AstraZeneca Plc - Company Profile
Powered by
All the data and insights you need on AstraZeneca Plc in one report.
- Save hours of research time and resources with
our up-to-date AstraZeneca Plc Strategy Report
- Understand AstraZeneca Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreAstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
AstraZeneca Plc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
- | Accolate |
Oncology: | Arimidex |
Calquence: Acalabrutinib | Atacand |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Acquisitions/Mergers/Takeovers | In June, the company acquired Fusion Pharmaceuticals Inc for US$2.4 billion. |
2024 | Contracts/Agreements | In June, the company partnered with Tempus to support the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer. |
2024 | Plans/Strategy | In May, the company announced its plans to establish a US$1.5 billion manufacturing facility in Singapore. |
Competitor Comparison
Key Parameters | AstraZeneca Plc | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
---|---|---|---|---|---|
Headquarters | United Kingdom | United States of America | Switzerland | United States of America | United States of America |
City | Cambridge | New Brunswick | Basel | Rahway | New York |
State/Province | England | New Jersey | - | New Jersey | New York |
No. of Employees | 89,900 | 131,900 | 103,605 | 72,000 | 88,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Pascal Soriot | Chief Executive Officer; Director | Executive Board | 2012 | - |
Aradhana Sarin | Director; Chief Financial Officer | Executive Board | 2021 | - |
Marc Dunoyer | Chief Strategy Officer; Chief Executive Officer - Alexion | Senior Management | 2021 | - |
Pam P. Cheng | Chief Sustainability Officer; Executive Vice President - Operations and Information Technology | Senior Management | 2023 | - |
Jeff Pott | Chief Human Resources Officer; Chief Compliance Officer; General Counsel | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer